News
Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...
Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...
In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...
Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...
21h
Clinical Trials Arena on MSNEli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLLEli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...
We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim ...
Eli Lilly’s Revenues have risen 39% from $35 billion in 2020 to $34 billion in 2023. This can be attributed to market share gains for some of its drugs, including Mounjaro, Verzenio, and Zyprexa.
Investors can see that Eli Lilly's P/S ratio of 17 is about two full turns higher than competitor Novo Nordisk. However, for most of 2023, the company was trading at a P/S ratio either lower or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results